Merck in Talks to Acquire Revolution Medicines Valued at $32 Billion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: stocktwits
- Acquisition Talks: Merck is in discussions to acquire Revolution Medicines, with a deal valued between $28 billion and $32 billion, potentially announced later this month, which would significantly enhance Revolution's market position.
- Market Reaction: Despite CEO Goldsmith's failure to confirm acquisition talks, Revolution Medicines' shares dipped 1% on Monday, reflecting market uncertainty around the acquisition news, with a current market cap of approximately $22.65 billion.
- Analyst Insights: Stifel analyst Laura Prendergast noted that updates from Revolution's pipeline lead her to believe the speculated $28-32 billion valuation might be low, prompting a reassessment of the stock's target price and 'Buy' rating, indicating a reevaluation of its potential value in the market.
- Future Outlook: Goldsmith emphasized that 2026 will be a year of growing impact for Revolution Medicines, with key milestones expected across clinical programs, indicating the company's ongoing development potential in cancer therapies.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABBV is 248.67 USD with a low forecast of 204.00 USD and a high forecast of 289.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
24 Analyst Rating
15 Buy
9 Hold
0 Sell
Moderate Buy
Current: 220.080
Low
204.00
Averages
248.67
High
289.00
Current: 220.080
Low
204.00
Averages
248.67
High
289.00
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
